Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial cardiolipin hydrolase (PLD6) is a mitochondrial outer membrane enzyme of the phospholipase D family with dual function as both a cardiolipin hydrolase and a single-strand specific endonuclease[1][2][5][6][12]. PLD6 is responsible for the hydrolysis of cardiolipin to generate phosphatidic acid (PA), a signaling lipid essential for mitochondrial membrane fusion processes[2][3][12]. It also has a critical role in the biogenesis of PIWI-interacting RNAs (piRNAs), where its nuclease activity is indispensable for the processing of precursor piRNA transcripts, especially during spermatogenesis, thereby safeguarding the genome against transposon-induced instability[1][3][5][6]. Loss or dysfunction of PLD6 disrupts mitochondrial dynamics and piRNA production, leading to meiotic arrest and male infertility, with associated defects in genome methylation and germ cell development[3][5]. PLD6 is a conserved protein with a characteristic H(x)K(x4)D motif that mediates its enzymatic activity, and it interacts with several mitochondrial proteins to coordinate mitochondrial dynamics and quality control[3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial cardiolipin hydrolase (PLD6).